Figure 1
Figure 1. Analysis of hepcidin expression and serum transferrin saturation in WT mice treated with an RNAi therapeutic directed against Tmprss6. (A) Total mRNA harvested 24 hours after treatment from WT mice dosed with various concentrations of LNP-formulated Tmprss6 siRNA (LNP-Tmprss6) or a luciferase control (LNP-Luc) and Tmprss6 or hepcidin (Hamp) mRNA (A) was assessed by quantitative real-time PCR, normalized to β-actin (Actb), and then expressed relative to the LNP-Luc value the mean value of which was defined as 1.0. (B) Four-week time-course analysis of Tmprss6 or hepcidin mRNA expression and transferrin saturation after treatment with 0.3 mg/kg of PBS, LNP-Luc, or LNP-Tmprss6. Ratios are expressed ± SEM (n = 5 in each group).

Analysis of hepcidin expression and serum transferrin saturation in WT mice treated with an RNAi therapeutic directed against Tmprss6. (A) Total mRNA harvested 24 hours after treatment from WT mice dosed with various concentrations of LNP-formulated Tmprss6 siRNA (LNP-Tmprss6) or a luciferase control (LNP-Luc) and Tmprss6 or hepcidin (Hamp) mRNA (A) was assessed by quantitative real-time PCR, normalized to β-actin (Actb), and then expressed relative to the LNP-Luc value the mean value of which was defined as 1.0. (B) Four-week time-course analysis of Tmprss6 or hepcidin mRNA expression and transferrin saturation after treatment with 0.3 mg/kg of PBS, LNP-Luc, or LNP-Tmprss6. Ratios are expressed ± SEM (n = 5 in each group).

Close Modal

or Create an Account

Close Modal
Close Modal